Journal
DRUG DELIVERY
Volume 24, Issue 2, Pages 81-93Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/10717544.2017.1399299
Keywords
Dendrimers; contrast agent; PET; radiolabeling; positron isotope
Categories
Funding
- National Natural Science Foundation of China [81671712, 81401440, 81761148028, 21773028]
- Science and Technology Commission of Shanghai Municipality [17540712000]
- Fundamental Research Funds for the Central Universities
- Shanghai Sailing Program [16YF1409300]
- FCT-Fundacao para a Ciencia e a Tecnologia (CQM, Portuguese Government) [PEst-OE/QUI/UI0674/2013]
- ARDITI-Agencia Regional para o Desenvolvimento da Investigacao Tecnologia e Inovacao through Centro de Quimica da Madeira-CQM + (Madeira 14-20) [M1420-01-0145-FEDER-000005]
Ask authors/readers for more resources
Positron emission tomography (PET) imaging offers physiological and biological information through the in vivo distribution of PET agents for disease diagnosis, therapy monitoring and prognosis evaluation. Due to the unique structural characteristics allowing for facile modification of targeting ligands and radionuclides, dendrimers can be served as a versatile scaffold to build up various PET imaging agents, and significant breakthroughs have been made in this field over the past decades. This review focuses on the recent advances in dendrimer-based contrast agents for PET imaging of cancer, cardiovascular and other diseases. In particular, radiolabeling strategies for different PET isotopes are described in detail. Several challenges involved in clinical translation of radiolabeled dendrimers are also discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
